Lucentis

Lucentis (ranibizumab) is a humanised recombinant monoclonal antibody fragment that is specific for all isoforms of human VEGF-A.

By preventing binding of VEGF-A to its receptors, Lucentis reduces endothelial cell proliferation, neovascularisation and vascular leakage¹. It has been shown to maintain and in some cases improve visual acuity in patients with the wet type of agerelated macular degeneration (AMD).^2-3

Lucentis is an intravitreal injection designed to quickly and fully penetrate all layers of the retina. The recommended dosing regimen for Lucentis is 0.5 mg or 0.3 mg given once a month. Lucentis is approved in Australia and is available on PBS Authority Prescription for subfoveal neovascular AMD.

References:

1. Lucentis Product Information.
2. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 2006;355(14):1419-1431.
3. Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin PDT for neovascular AMD: two year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.

[/vc_column_text][/vc_column]